| abstract |
The present invention relates to a combination of CYP2D6 and OPRM1 polymorphism markers for predicting tramadol-related vomiting side effects and a method for predicting tramadol-related side effects using the same, and more specifically, the activity-related genotype of CYP2D6, a major metabolic enzyme of active tramadol, and the 40th amino acid of OPRM1 protein. Certain combination marker groups (EM-GG, IM-AG) of polymorphic A118G (rs1799971), which change the sequence from asparagine to aspartic acid, reduce the risk of vomiting side effects of tramadol by the combination of specific genotypes of the two genes. Significantly associated with, it can be useful for predicting the genetic predisposition of the risk of predose side effects of tramadol-containing drugs. |